We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Bosch Exhibits Vivalytic All-in-One Analyzer for PCR Rapid Tests at MEDICA 2021

By LabMedica International staff writers
Posted on 18 Nov 2021

Bosch Healthcare Solutions GmbH (Waiblingen, Germany) exhibited its universal platform for molecular diagnostics that allows users to analyze a wide variety of sample materials in a fully automated way in a short time at MEDICA 2021. More...

The Vivalytic Analyzer from Bosch that was on display at the event allows infectious diseases to be diagnosed more quickly and easily than is the case today with manual tests in hospitals, laboratories, and medical practices. The platform combines different analysis methods in one device and is open to providers of further tests. The platform unites a wide spectrum of tests with a varying number of clinically relevant parameters on one device. The Vivalytic Analyzer enables fully automated PCR testing in laboratory quality – fast and directly at the point of care. The Vivalytic system consists of just a compact analysis device and cartridges the size of a smartphone. This enables rapid PCR tests to be carried out directly on site.

The Vivalytic Analyzer unites a wide variety of innovative technologies in one compact device. With only a touch display, a slot for inserting the test cartridge, a button and a scanner, the Analyser is very intuitive to use. This minimalistic design makes the Vivalytic system very user-friendly: medical professionals require only minimal training to be able to safely operate the Analyzer. Different types of samples can be tested fully automated with the Vivalytic Analyzer. The innovative technology reduces the need for manual preparation. The analyzer takes over this task before the analysis and evaluation takes place.

Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide. Results for positive samples are even delivered in less than 30 minutes. As a multiplex test, it simultaneously checks patient samples for the SARS-CoV-2 virus and nine other respiratory diseases in under two and a half hours. Bosch’s new rapid test is predestined for decentralized use in mobile test centers at freeway service stations or in airports. People who take the test can obtain a reliable result while at the testing site. Available now in Europe, the CE-approved test helps avoid time in quarantine, relieve laboratories, and make travel and work safer again.

Related Links:
Bosch Healthcare Solutions GmbH 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Pipette Calibration System
Artel PCS®
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.